Aerovate Therapeutics logo

Aerovate TherapeuticsNASDAQ: AVTE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 June 2021

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$79.39 M
-90%vs. 3y high
40%vs. sector
-vs. 3y high
-vs. sector
-91%vs. 3y high
37%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:42:31 GMT
$2.75+$0.22(+8.70%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

AVTE Latest News

INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. - AVTE
prnewswire.com03 November 2024 Sentiment: -

NEW YORK , Nov. 3, 2024 /PRNewswire/ --  Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE ), relating to a proposed merger with Jade Biosciences.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders
prnewswire.com01 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 1, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Aerovate Therapeutics, Inc. (NASDAQ: AVTE)'s  merger with Jade Biosciences. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company.

AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders
businesswire.com31 October 2024 Sentiment: NEGATIVE

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) and Jade Biosciences is fair to Aerovate shareholders. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company. Halper Sadeh encourages Aerovate shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212.

Aerovate Therapeutics to Explore Strategic Alternatives
globenewswire.com08 July 2024 Sentiment: NEGATIVE

WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.

Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC
globenewswire.com21 June 2024 Sentiment: NEGATIVE

ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (NASDAQ: AVTE) complied with federal securities laws. On June 17, 2024, Aerovate announced topline results from the Phase 2b portion of the Phase 2b/Phase 3 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial and stated that “the study did not meet its primary endpoint for improvement in pulmonary arterial hypertension (“PVR”) compared to placebo for any of the studied doses or show meaningful improvements in the secondary endpoint of change in six minute walk distance.” Following this news, the price of the Company's stock dropped.

Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm
globenewswire.com20 June 2024 Sentiment: NEGATIVE

Investors can contact the law firm at no cost to learn more about recovering their losses

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
globenewswire.com17 June 2024 Sentiment: NEGATIVE

AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
seekingalpha.com11 June 2024 Sentiment: POSITIVE

Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size is expected to reach $12.2 billion by 2032. Aerovate has been able to take what was achieved with oral Imatinib and convert it to a dry inhaled powder that can be used to treat pulmonary arterial hypertension.

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
globenewswire.com21 May 2024 Sentiment: POSITIVE

Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHCT continues at more than 120 sites globally WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today presented a poster outlining baseline characteristics from all patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) at the American Thoracic Society (ATS) 2024 International Conference taking place in San Diego, CA.

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
GlobeNewsWire27 March 2024 Sentiment: NEUTRAL

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster presentation at the 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, in San Diego, CA. The presentation will provide baseline characteristics from patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial evaluating the safety and efficacy of AV-101 in adults with pulmonary arterial hypertension.

What type of business is Aerovate Therapeutics?

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

What sector is Aerovate Therapeutics in?

Aerovate Therapeutics is in the Healthcare sector

What industry is Aerovate Therapeutics in?

Aerovate Therapeutics is in the Biotechnology industry

What country is Aerovate Therapeutics from?

Aerovate Therapeutics is headquartered in United States

When did Aerovate Therapeutics go public?

Aerovate Therapeutics initial public offering (IPO) was on 30 June 2021

What is Aerovate Therapeutics website?

https://aerovatetx.com

Is Aerovate Therapeutics in the S&P 500?

No, Aerovate Therapeutics is not included in the S&P 500 index

Is Aerovate Therapeutics in the NASDAQ 100?

No, Aerovate Therapeutics is not included in the NASDAQ 100 index

Is Aerovate Therapeutics in the Dow Jones?

No, Aerovate Therapeutics is not included in the Dow Jones index

When was Aerovate Therapeutics the previous earnings report?

No data

When does Aerovate Therapeutics earnings report?

The next expected earnings date for Aerovate Therapeutics is 13 November 2024